Levy Richard S
Director at MDGL; EVP, Chief Drug Dev Officer at INCY
- Sold, on record
- $70.7M
- Dollars the filings state
- Form 4 sales
- 39
- Latest May 22, 2026
- Form 144 notices
- 1
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale INCYPlan not statedJan 6 2016
Sold 3,937 shares at $101.86 ($401k)
Levy Richard S, EVP, Chief Drug Dev Officer
Sold 18.9% of holdings ($2.1M position)16,926 shares left0.5x usual sizeFiling
- 2 Form 4 sale MDGLUnusualJan 17 +2568 days
Sold 22,489 shares at $293.15 ($6.6M)
Levy Richard S, Director
Sold 71.2% of holdings ($9.3M position)9,100 shares leftFirst sale on recordFiling
- 3 Form 144 notice MDGLNoticeApr 1 +440 days
Filed to sell 11,000 shares ($2.9M)
Levy Richard S, Director
10b5-1 planFiling
- 4 Form 4 sale MDGLRoutineApr 1 same day
Sold 11,000 shares at $257.48 ($2.8M)
Levy Richard S, Director
10b5-1 planSold 51.6% of holdings ($5.5M position)10,298 shares leftFollows a Form 144Filing
- 5 Form 4 sale MDGLRoutineNov 1 +214 days
Sold 5,000 shares at $300.94 ($1.5M)
Levy Richard S, Director
10b5-1 planSold 31.2% of holdings ($4.8M position)11,012 shares leftFiling
- 6 Form 4 sale MDGLRoutineNov 7 +6 days
Sold 5,000 shares at $350.00 ($1.8M)
Levy Richard S, Director
10b5-1 planSold 31.2% of holdings ($5.6M position)11,012 shares left0.5x usual sizeFiling
- 7 Form 4 sale MDGLRoutineNov 13 +371 days
Sold 8,500 shares at $520.96 ($4.4M)
Levy Richard S, Director
10b5-1 planSold 28.6% of holdings ($15.5M position)21,197 shares left1.7x usual sizeFiling
- 8 Form 4 sale MDGLRoutineMay 22 +190 days
Sold 5,682 shares at $515.44 ($2.9M)
Levy Richard S, Director
10b5-1 planSold 20.5% of holdings ($14.3M position)22,015 shares left1.1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (40)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | MDGL | Director | Form 4 sale | 5,682 | $2.9M | 20.5% | Routine | SEC |
| Nov 13, 2025 | MDGL | Director | Form 4 sale | 8,500 | $4.4M | 28.6% | Routine | SEC |
| Nov 7, 2024 | MDGL | Director | Form 4 sale | 5,000 | $1.8M | 31.2% | Routine | SEC |
| Nov 1, 2024 | MDGL | Director | Form 4 sale | 5,000 | $1.5M | 31.2% | Routine | SEC |
| Apr 1, 2024 | MDGL | Director | Form 4 sale | 11,000 | $2.8M | 51.6% | Routine | SEC |
| Apr 1, 2024 | MDGL | Director | Form 144 notice | 11,000 | $2.9M | Notice | SEC | |
| Jan 17, 2023 | MDGL | Director | Form 4 sale | 22,489 | $6.6M | 71.2% | Unusual | SEC |
| Jan 6, 2016 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 3,937 | $401k | 18.9% | Plan not stated | SEC |
| Dec 7, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 3,937 | $418k | 18.9% | Plan not stated | SEC |
| Nov 6, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 3,936 | $459k | 18.9% | Plan not stated | SEC |
| Oct 6, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 3,937 | $481k | 18.9% | Plan not stated | SEC |
| Sep 11, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 4,301 | $559k | 20.3% | Plan not stated | SEC |
| Sep 8, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 3,937 | $468k | 15.6% | Plan not stated | SEC |
| Aug 6, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 3,936 | $441k | 15.6% | Plan not stated | SEC |
| Jul 15, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 70,217 | $8.4M | 76.8% | Unusual | SEC |
| Jul 6, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 3,937 | $421k | 15.6% | Plan not stated | SEC |
| Jun 19, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 20,000 | $2.2M | 48.5% | Unusual | SEC |
| Jun 8, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 3,937 | $424k | 15.6% | Plan not stated | SEC |
| May 6, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 7,412 | $737k | 25.9% | Unusual | SEC |
| Apr 6, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 25,000 | $2.2M | 54.1% | Unusual | SEC |
| Mar 6, 2015 | INCY | EVP, Chief Drug Dev Officer | Form 4 sale | 25,000 | $2.2M | 54.1% | Unusual | SEC |
| Feb 17, 2015 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 12,000 | $923k | 39.7% | Unusual | SEC |
| Feb 6, 2015 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 25,000 | $1.9M | 57.9% | Unusual | SEC |
| Jan 16, 2015 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 12,000 | $877k | 39.7% | Unusual | SEC |
| Jan 6, 2015 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 25,000 | $1.8M | 57.9% | Unusual | SEC |
| Dec 16, 2014 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 12,000 | $868k | 39.7% | Unusual | SEC |
| Nov 17, 2014 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 12,000 | $840k | 39.7% | Unusual | SEC |
| Oct 16, 2014 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 8,000 | $392k | 65.0% | Unusual | SEC |
| Sep 16, 2014 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 8,000 | $381k | 65.0% | Unusual | SEC |
| Aug 18, 2014 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 8,000 | $416k | 65.0% | Unusual | SEC |
| Jul 16, 2014 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 8,000 | $385k | 65.0% | Unusual | SEC |
| Jun 16, 2014 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 8,000 | $431k | 65.0% | Unusual | SEC |
| May 16, 2014 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 8,000 | $405k | 65.0% | Unusual | SEC |
| Feb 14, 2014 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 231,096 | $15.3M | 98.2% | Unusual | SEC |
| Sep 6, 2013 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 25,000 | $882k | 100.0% | Unusual | SEC |
| May 13, 2013 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 55,699 | $1.2M | 92.8% | Unusual | SEC |
| Feb 15, 2013 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 98,440 | $2.2M | 100.0% | Unusual | SEC |
| Apr 27, 2012 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 30,000 | $689k | 100.0% | Unusual | SEC |
| Jan 18, 2011 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 40,310 | $637k | 100.0% | Unusual | SEC |
| Mar 15, 2010 | INCY | EVP, Chief Drug Dev&Medical Of | Form 4 sale | 20,000 | $259k | 100.0% | Unusual | SEC |